Synergistic Effects of Nanoemulsion and Deferiprone (1, 2 Dimethyl-3-Hydroxypyrid-4-One) on Multi-Drug Resistant Acinetobacter baumannii

Nosocomial infections caused by Acinetobacter baumannii (A. baumannii) are exceedingly difficult to treat, particularly in immune-compromised patients. Nanoemulsions (NEs) are a distinctive category of disinfectants that have wide range of bactericidal, fungicidal and antiviral properties by damaging their outer membranes. The inhibiting potential of iron chelators such as deferiprone (DF) used as remedial agent for different microbial groups. Combining new generation disinfectant NEs and the iron chelator DF is a logical approach to control of A. baumannii planktonic and biofilm infections. Present studies investigated the bactericidal efficacy of NE with DF by testing their minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) against four strains of A. baumannii. We analyzed adherence of the planktonic form both with and without deferiprone to determine possible enhancement effects. The mechanism of nanoemulsion with deferiprone (NE/DF) was quantified by LIVE/DEAD staining biofilm assay and scanning electron microscopy. DF does not affect the stability of the nanoemulsion and the combined forms show high stability. From MBC, NE/DF showed enhanced activity up to 2to 3.3-fold compared to nanoemulsion and deferiprone alone. Combined nanoemulsion with deferiprone showed higher adherence inhibition compared to the individual forms. From confocal imaging, the level of dead cell intensity was 84.9% to 96.6% in NE/DF treated groups. Bacteria treated with NE, DF and NE/DF confirms morphological variations when compared to pili-bonded integrated control cells. We propose that biofilm destruction starts from pili removal followed by membrane destruction. These results leave a concrete evidence for the employment of nanoemulsion with deferiprone for the treatment of against drug resistant A. baumannii.

[1]  D. Zurawski,et al.  Antibacterial Activities of Iron Chelators against Common Nosocomial Pathogens , 2012, Antimicrobial Agents and Chemotherapy.

[2]  Wangxue Chen,et al.  In Vitro and In Vivo Biological Activities of Iron Chelators and Gallium Nitrate against Acinetobacter baumannii , 2012, Antimicrobial Agents and Chemotherapy.

[3]  M. Hossain,et al.  Iron chelation therapy and thalassemia - an overview. , 2011, Mymensingh medical journal : MMJ.

[4]  I. Wagner-Döbler,et al.  The luxS mutation causes loosely-bound biofilms in Shewanella oneidensis , 2011, BMC Research Notes.

[5]  K. Karimian,et al.  Advances in iron chelation: an update , 2011, Expert opinion on therapeutic patents.

[6]  S. Nekhai,et al.  Iron Chelators of the Di-2-pyridylketone Thiosemicarbazone and 2-Benzoylpyridine Thiosemicarbazone Series Inhibit HIV-1 Transcription: Identification of Novel Cellular Targets—Iron, Cyclin-Dependent Kinase (CDK) 2, and CDK9 , 2011, Molecular Pharmacology.

[7]  V. Lee,et al.  Anti-cariogenic effect of a cetylpyridinium chloride-containing nanoemulsion. , 2010, Journal of dentistry.

[8]  R. Appelberg,et al.  Identification of a new hexadentate iron chelator capable of restricting the intramacrophagic growth of Mycobacterium avium. , 2010, Microbes and infection.

[9]  A. Gales,et al.  Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy , 2010, Expert review of anti-infective therapy.

[10]  K. Towner.  Acinetobacter: an old friend, but a new enemy. , 2009, The Journal of hospital infection.

[11]  Sung-Heui Shin,et al.  Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci , 2009, Journal of Korean medical science.

[12]  J. Svendsen,et al.  High in vitro antimicrobial activity of synthetic antimicrobial peptidomimetics against staphylococcal biofilms. , 2008, The Journal of antimicrobial chemotherapy.

[13]  J. Vila,et al.  Therapeutic options for Acinetobacter baumannii infections , 2008, Expert opinion on pharmacotherapy.

[14]  B. Spellberg,et al.  The iron chelator deferasirox protects mice from mucormycosis through iron starvation. , 2007, The Journal of clinical investigation.

[15]  P. Teixeira,et al.  Antimicrobial effects of a microemulsion and a nanoemulsion on enteric and other pathogens and biofilms. , 2007, International journal of food microbiology.

[16]  G. Waksman,et al.  Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria , 2006, Proceedings of the National Academy of Sciences.

[17]  C. L. Cardoso,et al.  Preliminary evaluation of adherence on abiotic and cellular surfaces of Acinetobacter baumannii strains isolated from catheter tips. , 2006, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[18]  M. Kaufmann,et al.  A prevalent, multiresistant clone of Acinetobacter baumannii in Southeast England. , 2004, The Journal of hospital infection.

[19]  T. Møretrø,et al.  Listeria monocytogenes : biofilm formation and persistence in food-processing environments , 2004 .

[20]  L. Actis,et al.  Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. , 2003, Microbiology.

[21]  I. Raad,et al.  In Vitro and Ex Vivo Activities of Minocycline and EDTA against Microorganisms Embedded in Biofilm on Catheter Surfaces , 2003, Antimicrobial Agents and Chemotherapy.

[22]  E. Nour,et al.  Comparison of hexamethyldisilazane and critical point drying treatments for SEM analysis of anaerobic biofilms and granular sludge. , 2003, Journal of electron microscopy.

[23]  É. Carniel,et al.  Comparison of the Effects of Deferiprone versus Deferoxamine on Growth and Virulence of Yersinia enterocolitica , 2002, Antimicrobial Agents and Chemotherapy.

[24]  M. Kierans,et al.  Microemulsions are membrane‐active, antimicrobial, self‐preserving systems , 2000, Journal of applied microbiology.

[25]  James R. Baker,et al.  Prevention of Murine Influenza a Virus Pneumonitis by Surfactant Nano-Emulsions , 2000, Antiviral chemistry & chemotherapy.

[26]  J. Baker,et al.  A novel surfactant nanoemulsion with broad-spectrum sporicidal activity against Bacillus species. , 1999, The Journal of infectious diseases.

[27]  R. Ellison,et al.  Killing of gram-negative bacteria by lactoferrin and lysozyme. , 1991, The Journal of clinical investigation.

[28]  H. Ennis.  Bacterial Resistance to the Synergistic Antibiotics of the PA 114, Streptogramin, and Vernamycin Complexes , 1967, Journal of bacteriology.

[29]  L. Leive,et al.  Release of lipopolysaccharide by EDTA treatment of E. coli. , 1965, Biochemical and biophysical research communications.

[30]  V. Lee,et al.  Antimicrobial activity of nanoemulsion on cariogenic planktonic and biofilm organisms. , 2012, Archives of oral biology.

[31]  J. Bartlett,et al.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  M. Mulvey,et al.  Acinetobacter baumannii in casualties returning from Afghanistan. , 2007, The Canadian journal of infection control : the official journal of the Community & Hospital Infection Control Association-Canada = Revue canadienne de prevention des infections.

[33]  Sung-Heui Shin,et al.  Ferrophilic characteristics of Vibrio vulnificus and potential usefulness of iron chelation therapy. , 2007, The Journal of infectious diseases.

[34]  P. Stoodley,et al.  Biofilm Structure, Behavior, and Hydrodynamics , 2004 .

[35]  J. Baker,et al.  The fungicidal activity of novel nanoemulsion (X8W60PC) against clinically important yeast and filamentous fungi , 2004, Mycopathologia.

[36]  J. Baker,et al.  A novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi. , 2001, Microbiological research.

[37]  M. Lawrence,et al.  Microemulsion-based media as novel drug delivery systems. , 2000, Advanced drug delivery reviews.